SLC5A2 and type 2 diabetes mellitus: In our cohort, 9 patients (19.1%) with T2DM were receiving SGLT2 inhibitors, and 2 patients (4.3%) were treated with GLP-1 receptor agonists, while none of the controls were on these therapies.